UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
15
CERTIFICATION
AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS
UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.
Commission
File Number 001-40388
ANEBULO
PHARMACEUTICALS, INC.
(Exact
name of registrant as specified in its charter)
Anebulo
Pharmaceuticals, Inc.
1017 Ranch Road 620 South, Suite 107
Lakeway, TX 78734
(512) 598-0931
(Address,
including zip code, and telephone number, including area code, of registrant’s principal executive offices)
Common
Stock, $0.001 par value per share
(Title of each class of securities
covered by this Form)
None.
(Titles
of all other classes of securities for which a duty to file reports under section 13(a) or
15(d) remains)
Please
place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:
| Rule 12g-4(a)(1) |
☒ |
| Rule 12g-4(a)(2) |
☐ |
| Rule 12h-3(b)(1)(i) |
☒ |
| Rule 12h-3(b)(1)(ii) |
☐ |
| Rule 15d-6 |
☐ |
| Rule 15d-22(b) |
☐ |
Approximate
number of holders of record as of the certification or notice date: 71
Pursuant
to the requirements of the Securities Exchange Act of 1934 Anebulo Pharmaceuticals, Inc. has caused this certification/notice to be signed
on its behalf by the undersigned duly authorized person.
| Date:
March 2, 2026 |
By: |
/s/
Richard Anthony Cunningham |
| |
Name: |
Richard
Anthony Cunningham |
| |
Title: |
Chief
Executive Officer and Interim Chief Financial Officer |
